SB-728mR-HSPC / Sangamo Therap - LARVOL DELTA

Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Aug 2025 ➔ Aug 2026 | Trial primary completion date: Aug 2025 ➔ Aug 2026

Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD34

Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial primary completion date: Sep 2020 ➔ Aug 2025

Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD34

Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Dec 2024 ➔ Jun 2025

Trial completion date • Human Immunodeficiency Virus • Infectious Disease • CD34 • CD4

Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/progenitor Cells in HIV-1 Infected Patients (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Aug 2024 ➔ Dec 2024

Trial completion date • Human Immunodeficiency Virus • Infectious Disease • CD34 • CD4

Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Dec 2023 ➔ Aug 2024

Trial completion date • Human Immunodeficiency Virus • Infectious Disease • CD34 • CD4

Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Dec 2022 ➔ Dec 2023

Trial completion date • Human Immunodeficiency Virus • Infectious Disease • CD34

Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients (clinicaltrials.gov) - P1; N=12; Active, not recruiting; Sponsor: City of Hope Medical Center; Trial completion date: Mar 2021 ➔ Dec 2022; Trial primary completion date: Mar 2021 ➔ Dec 2021

Clinical • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD34

Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients (clinicaltrials.gov) - P1; N=12; Active, not recruiting; Sponsor: City of Hope Medical Center; Trial completion date: Apr 2022 ➔ Mar 2021; Trial primary completion date: Apr 2022 ➔ Mar 2021

Clinical • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD34